277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma

Background

To characterize ductal adenocarcinoma of the prostate by comparing VASH1 expression levels in ductal and acinar adenocarcinoma of the prostate.

Methods

125 patients who underwent radical prostatectomy or transrectal resection over the past 5 years, 14 patients diagnosed with ductal adenocarcinoma and 20 patients with acinar adenocarcinoma with Gleason scores of 4+4 were included in the study. VASH1 density was taken as the number of activated endothelial cells (number of vessels per mm2), microvessel density (MVD) was determined through CD34 expression, all results were obtained by immunohistochemistry. The main method for evaluating the results was to determine the presence of a relationship between MVD and VASH1 density in ductal and acinar adenocarcinoma, the secondary method for evaluating the results was the oncological outcomes of these forms of cancer.

Results

9 patients (64.3%) with ductal adenocarcinoma were diagnosed with advanced clinical stage and 5 patients (35.7%) died of cancer during a median follow-up period of 56.0 months. VASH1 density (mean ± SD) in ductal and acinar adenocarcinoma was 45.1 ± 18.5 vs. 16.1 ± 21.0 (p < 0.001), respectively, while MVD (mean ± SD) in ductal and acinar adenocarcinoma was 65.3 ± 21.9 versus 80.8 ± 60.7. (p = 0.666), respectively. The five-year survival rate for high and low VASH1 expression was 70.0% and 100.0% (p = 0.006), respectively. High expression of VASH1 and diagnosis of ductal adenocarcinoma were important predictors of survival.

Conclusions

Ductal adenocarcinoma has more aggressive growth and higher expression of VASH1 than acinar adenocarcinoma, with MVD rates being equivalent in both forms of prostate cancer. The obtained results suggest that the level of VASH1 expression may be a new biomarker for the aggressive course of ductal adenocarcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Republican Cancer Research Center of Uzbekistan.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.